Fortschreibung der KoDiM-Studie: Kosten des Diabetes mellitus 2000–2009

Abstract

Cost of illness studies create transparency on the economic dimension of diseases. By now, the CoDiM study, based on administrative data of AOK Hesse und KV Hesse, identifies costs of people with diabetes and diabetes related excess costs in Germany for a period of 10 years. To date, additionally adjusted results are available by accounting for effects caused by inflation and ageing of the population. From 2000 to 2009 the number of treated patients with diabetes increased by 49 %, adjusted for age by 31 %. Mean cost of patients with diabetes and diabetes related excess costs per capita turned out to be relatively stable over the time period observed. The relation of cost per patient with diabetes to cost of patients without diabetes didn't change. Due to the increase of the number of treated patients with diabetes in the past 10 years, the total direct cost, dependant on the approach of calculation (adjusting or not for inflation and ageing effects), rose by 28 % to 70 %, the therein included diabetes excess cost by 24 % to 61 %.

Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies

“…[7][8][9][10][11][12][13][14][15][16] For example, a study based on administrative health claims data (AOK/KV Hesse) showed that the excess direct medical costs of diabetes mellitus in 2009 averaged €21 billion in Germany. 17 Studies from the USA and England reported annual direct medical costs of $176 billion and £10 billion, respectively. 18 19 As one of the leading causes of morbidity and mortality, diabetes leads to a broad range of microvascular and macrovascular complications, such as retinopathy, nephropathy, neuropathy, stroke and myocardial infarction.…”

Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland

“…Trotz des Wiissens um eine hohe, vermutlich in den letzten Jahrzehnten gestiegenen Prävalenz und Inzidenz in Deutschland überrascht, wie wenige Studien umfassende populationsbezogene und methodisch vertretbare Aussagen zur Prävalenz und Inzidenz von DM2 in Deutschland treffen. Verfügba-re Studien basieren entweder auf Angaben von Patienten [10,11,12,24], auf ausschließlich regionalen Daten gesetzlicher Krankenversicherungen (GKV) [8,9,13,14], Untersuchungen in einzelnen Bundesgebieten [17,19,21] oder nahezu 25 Jahre alten Daten aus der ehemaligen DDR [6]. Hinzu kommt, dass ein Großteil der Studien keine bzw.…”

Serum Fetuin A Level, Liver Enzymes Activities and Insulin Resistance in Patients with Type 2 Diabetes

“…The disease may be acquired or inherited. High prevalence and incidence of type 2 diabetes make it an important disease (Koster et al, 2012). Prevalence of type 2 diabetes mellitus is raising worldwide (Gadsby, 2002;De Lusignan et al, 2005;Passa, 2002).…”